ORIC Pharmaceuticals’ (ORIC) Outperform Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report released on Thursday,RTT News reports. They currently have a $20.00 target price on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares […]
Wedbush reiterated their outperform rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report released on Thursday,RTT News reports. They currently have a $20.00 target price on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares […]
